Compare Celestica Inc (CLS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celestica Inc vs Merck & Co., Inc. — how do they compare? Celestica Inc trades at $333.51 (market cap $39.28B), while Merck & Co., Inc. trades at $123.51 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 7.6× Celestica Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| CLS | MRK | |
|---|---|---|
Market Cap | $39.28B | $298.31B |
Sector | Technology | Health |
52-Week High | $472.40 | $129.52 |
52-Week Low | $156.91 | $77.60 |
Enterprise Value | $39.68B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Celestica (CLS) trades at $345.18, down 4.08% over 24 hours, with technical indicators showing a bearish trend near key support at $339. The company demonstrates strong fundamentals with Q1 2026 EPS of $2.16 beating estimates, revenue growth accelerating to 55.55% YoY, and a robust ROE of 52.45%. Recent leadership appointments and raised FY2026 revenue guidance to $19 billion reflect operational momentum amid AI and data center demand tailwinds.
Wall Street maintains a bullish outlook with 63% buy ratings and a $440.10 consensus price target, implying 27% upside. Key risks include competitive pressures in the EMS sector and execution challenges in margin expansion. The stock's high P/E of 41.82 warrants monitoring, but earnings beats and institutional confidence support a positive investment case pending Q2 results on July 28, 2026.
Merck & Co. (MRK) trades at $123.6, down 0.35% on the day, with a bullish technical outlook supported by moving averages and an oversold RSI. The company reported strong earnings beats in recent quarters, with 2025 revenue of $65.01B and net income of $18.25B, though Q1 2026 saw a loss. Analyst consensus is strongly bullish with a $137.30 price target, and recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is positive, driven by robust profitability, strategic acquisitions, and Wall Street support. Key risks include integration challenges from the Terns deal, patent expirations, and macroeconomic pressures on healthcare spending. The stock offers a dividend yield with a recent $0.85 payout, but investors should monitor debt levels, which rose to 36.06% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
